<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01077180</url>
  </required_header>
  <id_info>
    <org_study_id>360005-001</org_study_id>
    <nct_id>NCT01077180</nct_id>
  </id_info>
  <brief_title>Rheos Feasibility Trial</brief_title>
  <official_title>Rheos Feasibility Trial- A Study of Baroreflex Hypertension TherapyTM in Refractory Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CVRx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CVRx, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Rheos Feasibility Trial is designed to assess safety, device performance, and protocol
      parameters of the CVRx Rheos Baroreflex Therapy in patients with severe hypertension that are
      refractory to full drug therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rheos Feasibility Study</measure>
    <time_frame>13 months</time_frame>
    <description>To summarize the efficacy of the Rheos System by estimating the reduction of systolic blood pressure associated with activation of the Rheos System at 4 and 13 months post implant when compared to baseline (1-month post implant).
To describe the safety of the Rheos System by summarizing all system related adverse events and estimating the serious sytem related event-free rate through 4 and 13 months post-implant.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Rheos Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical Management</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantation of the Rheos System</intervention_name>
    <description>Open label</description>
    <arm_group_label>Rheos Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care medical management</intervention_name>
    <description>Patients will continue with medical therapy for standard of care of their hypertension.</description>
    <arm_group_label>Medical Management</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be at least 21 years of age.

          2. Have been assessed to have bilateral carotid bifurcations located at or below C3-C4.

          3. Have an office cuff systolic blood pressure greater than or equal to 160 mmHg and a
             24-hour ambulatory systolic blood pressure greater than or equal to 150 mmHg despite
             at least one month of full therapy with at least three (3) anti-hypertensive
             medications, of which at least one (1) must be a diuretic.

          4. Must be certified by the investigator hypertension specialist as compliant with taking
             full doses of medication.

          5. Have signed a CVRx approved informed consent for participation in this study.

        Exclusion Criteria:

          1. Have been diagnosed with:

               -  Baroreflex failure

               -  Cardiac bradyarrhythmias

               -  Chronic atrial fibrillation

          2. Had a heart transplant

          3. Have carotid atherosclerosis producing a 50% or greater reduction in linear diameter
             as determined by ultrasound or angiographic evaluation as determined within six months
             of enrollment in the trial.

          4. Have Grade C ulcerative plaques in the carotid artery as determined by ultrasound or
             angiographic evaluation.

          5. Have prior surgery or radiation in either carotid sinus region.

          6. Currently have implanted electrical medical devices such as cardiac pacing,
             defibrillation or neurologic stimulation systems.

          7. Are pregnant or contemplating pregnancy during the 13-month follow-up period.

          8. Currently undergoing dialysis.

          9. Have hypertension secondary to a treatable cause.

         10. Have clinically significant cardiac valvular disease.

         11. Are unable or unwilling to fulfill the protocol medication compliance and follow-up
             requirements.

         12. Are unlikely to survive the protocol follow-up period.

         13. Are enrolled in another concurrent clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2010</study_first_submitted>
  <study_first_submitted_qc>February 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2010</study_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

